During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The combined entity will leverage its complementary strengths to deliver unparalleled solutions in protein purification and stabilization
He has 29+ years’ comprehensive experience in world-class Formulations and API (for US and EU requirements) mainly related to injectables
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
Zydus Lifesciences and SBL have mutually decided to extend the date of closing upto March 31, 2025
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
This is used to treat central diabetes insipidus and bedwetting
Subscribe To Our Newsletter & Stay Updated
